Amino substituted pyridines as potent kinase inhibitors

1. A compound represented by the following structural formula:

or a pharmaceutically acceptable salt thereof, wherein:

B is pyridyl, wherein B is optionally and independently substituted with R 12 ′ and independently optionally and independently substituted with one or more R 12 groups in addition to R 3 ;

Z is O;

R 1 is —H, halogen, —CN, —NO 2 , or -T1-Q1;

T1 is absent or C1-10 aliphatic, wherein up to three methylene units of T1 are optionally and independently replaced by G wherein G is —O—, —S—, —S(O)—, —S(O) 2 —, —N(R 4 )—, or —C(O)—; T1 is optionally and independently substituted with one or more JT1;

Q1 is absent, a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Q1 is optionally and independently substituted with J1 and independently optionally and independently substituted with one or more R 13 groups;

J11 is —Y1-M1;

Y1 is absent, oxo, or C1-10 aliphatic wherein up to three methylene units of Y1 are optionally and independently replaced with G1 wherein G1 is —N(R $ )—, —O—, —S—, —C(O)—, —S(O)—, or —S(O) 2 —, Y1 is optionally and independently substituted with one or more JT1;

M1 is C1-6 aliphatic, C3-8 cycloaliphatic, haloC1-4 aliphatic, —O(haloC1-4 aliphatic), 3-8 membered heterocyclyl, 5-6 membered heteroaryl, phenyl, —OR $ , —SR $ , —N(R $ ) 2 , —C(O)R $ , —C(O) 2 R $ , —C(O)N(R $ ) 2 , —OC(O)R $ , —OC(O)N(R $ ) 2 , —NR $ C(O)R $ , —NR $ C(O) 2 R $ , —NR $ C(O)N(R $ ) 2 , —SO 2 N(R $ ) 2 , —NR $ S(O) 2 R $ , —S(O)R $ , —S(O) 2 R $ , —P(O)R $ , —P(O) 2 R $ , —P(O)(R $ ) 2 , or —PO(OR $ ) 2 ; M1 is optionally and independently substituted with one or more J; or M1 is absent, halogen, —N(O) 2 , or —CN;

R 2 is —H, halogen, —CN, —N(O) 2 , or optionally and independently substituted C1-C6 alkyl;

R 3 is -T2-Q2;

T2 is absent;

Q2 is 1,4-diazepane ring, wherein Q2 is optionally and independently substituted with J2 and independently optionally and independently substituted with one or more R 13 groups;

J2 is —Y2-M2;

Y2 is absent, oxo, or C1-10 aliphatic, wherein up to three methylene units of Y2 are optionally and independently replaced with G1′ wherein G1′ is —N(O)—, —O—, —S—, —C(O)—, —S(O)—, or —S(O) 2 —, Y2 is optionally and independently substituted with one or more JT2;

M2 is C1-6 aliphatic, C3-8 cycloaliphatic, haloC1-4 aliphatic, —O(haloC1-4 aliphatic), 3-8 membered heterocyclyl, heteroaryl, aryl, —OR $ , —SR $ , —N(R $ ) 2 , —C(O)R $ , —C(O) 2 R $ , —C(O)N(R $ ) 2 , —OC(O)R $ , —OC(O)N(R $ ) 2 , —NR $ C(O)R $ , —NR $ C(O) 2 R $ , —NR $ C(O)N(R $ ) 2 , —SO 2 N(R $ ) 2 , —NR $ S(O) 2 R $ , —S(O)R $ , —S(O) 2 R $ , —P(O)R $ , —P(O) 2 R $ , —P(O)(R $ ) 2 , or —PO(OR $ ) 2 ; wherein M2 is optionally and independently substituted with one or more J; or M2 is absent, halogen, —N(O) 2 , or —CN;

each J is independently halogen, C1-6 aliphatic, C3-6 cycloaliphatic, —NO 2 , —CN, —N(R $ ) 2 , —OR $ , —C(O)R $ , —C(O)N(R $ ) 2 , —C(O) 2 R $ , oxo, —O(haloC1-4 aliphatic), or halo C1-4 aliphatic;

R 4 is —H or an optionally and independently substituted C1-C6 alkyl;

each JT1 is independently halogen, —CN, —N(O) 2 , or hydroxy;

each JT2 is independently halogen, —CN, —N(O) 2 , or hydroxy;

each R $ is independently —H or C1-C6 alkyl;

each R 12 is independently halogen, amino, aminoalkyl, alkylaminoalkyl, alkoxy, hydroxy, —CN, —NO 2 , or optionally and independently substituted C1-C6 alkyl;

each R 12 ′ is independently halogen, amino, aminoalkyl, alkylaminoalkyl, alkoxy, hydroxy, —CN, —NO 2 , or optionally and independently substituted C1-C10 aliphatic wherein up to three methylene units are optionally and independently replaced by G′ wherein G′ is —O—, —S(O) p —, —N(R 4 )—, or —C(O)—, and each methylene unit is optionally and independently substituted with one or more JT3; or each R 12′ is cycloaliphatic, phenyl, heteroaryl, each independently and optionally substituted with one or more JT4;

each JT3 is independently halogen, —CN, —NO 2 , cycloaliphatic, or phenyl;

each JT4 is independently halogen, C1-C6 alkyl, or C1-C6 alkoxy;

each R 13 is independently halogen, amino, aminoalkyl, alkylaminoalkyl, alkoxy, hydroxy, —CN, —NO 2 , oxo or optionally and independently substituted C1-C6 alkyl; and

p is 0, 1 or 2.

2. The compound of claim 1 wherein:

R 2 is —H, halogen, —CN, —N(O) 2 , or C1-C6 alkyl optionally and independently substituted with one or more R 13 .

3. The compound of claim 2 wherein:

R 2 is —H.

4. The compound of claim 3 wherein:

R 1 is —H, halogen, or -T1-Q1;

T1 is absent or C1-10 aliphatic, wherein up to three methylene units of T1 are optionally and independently replaced by G wherein G is —O—, —N(R 4 )—, or —C(O)—; T1 is optionally and independently substituted with one or more JT1;

Q1 is absent, or a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Q1 is independently optionally and independently substituted with J1;

J1 is —Y1-M1;

Y1 is absent, oxo, or C1-10 aliphatic wherein up to three methylene units of Y1 are optionally and independently replaced with G1 wherein G1 is —N(R $ )—, —O—, —C(O)—, or —S(O) 2 —, Y1 is optionally and independently substituted with one or more JT1; and

M1 is C3-8 cycloaliphatic, 3-8 membered heterocyclyl, 5-6 membered heteroaryl, phenyl, —OR $ , —SR $ , —N(R $ ) 2 , —P(O)R $ , —P(O) 2 R $ , P(O)(R $ ) 2 , or PO(OR $ ) 2 , wherein M1 is optionally and independently substituted with one or more J; or M1 is absent, —CN, —NO 2 , or halogen.

5. The compound of claim 4 wherein:

T1 is absent or C1-10 aliphatic wherein up to three methylene units of T1 are optionally and independently replaced by G wherein G is —O—, or —N(R 4 )—; T1 is optionally and independently substituted with one or more JT1;

Y1 is absent or C1-10 aliphatic wherein up to three methylene units of Y1 are optionally and independently replaced with G1 wherein G1 is —N(R $ )—, —O— —C(O)—, or —S(O) 2 ; Y1 is optionally and independently substituted with one or more JT1; and

M1 is C3-8 cycloaliphatic, 3-8 membered heterocyclyl, 5-6 membered heteroaryl, phenyl, —N(R $ ) 2 , or —OR $ ; wherein M1 is optionally and independently substituted with one or more J; or M1 is absent, —CN, or halogen.

6. The compound of claim 5 wherein:

each J is independently halogen, C1-6 aliphatic, —NO 2 , —CN, —N(R $ ) 2 , —OR $ , —C(O)R $ , —C(O)N(O) 2 , —C(O) 2 R $ , oxo, or haloC1-4 aliphatic.

7. The compound of claim 6 wherein:

T1 is absent, C1-C10 alkyl, C2-10 alkenyl, or C2-C10 alkynyl wherein up to three methylene units of T1 are optionally and independently replaced by G wherein G is —O—, or —N(R 4 )—; T1 is optionally and independently substituted with one or more JT1;

Q1 is absent, phenyl, indolyl, quniolyl, isoindolyl, isoquinolyl, indazolyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cyclopropyl, pyrrolyl, pyrazolyl, imidazolyl, thienyl, benzothienyl, furyl, benzofuryl, piperidinyl, piperizinyl, pyrrolodinyl, pyrazinyl, pyrimidinyl, or pyridyl; wherein Q1 is optionally and independently substituted with J1;

Y1 is absent or C1-10 alkyl group wherein up to three methylene units of Y1 are optionally and independently replaced with G1 wherein G1 is —O—, Y1 is optionally and independently substituted with one or more JT1; and

M1 is phenyl, —N(R $ ) 2 , or —OR $ ; wherein M1 is optionally and independently substituted with one or more J; or M1 is absent, or —CN.

8. The compound of claim 4 wherein:

R 1 is —H, or halogen.

9. The compound of claim 7 wherein ring B is substituted with R 3 and independently optionally substituted with R 12 ′ and independently and optionally and independently substituted with one or more R 12 groups.

10. The compound of claim 9 wherein:

Y2 is absent, oxo, or C1-10 aliphatic wherein up to three methylene units of Y2 are independently and optionally replaced with G1′ wherein G1′ is —N(R $ )—, —O—, —C(O)—, or —S(O) 2 —, Y2 is optionally and independently substituted with one or more JT2;

M2 is C1-6 aliphatic, C3-8 cycloaliphatic, 3-8 membered heterocyclyl, 5-12 membered heteroaryl, 5-12 membered aryl, —N(R $ ) 2 , —OR $ , —C(O)R $ , —C(O) 2 R $ , —S(O)R $ , or —S(O) 2 R $ wherein M2 is optionally and independently substituted with one or more J; or M2 is absent, —NO 2 , or —CN; and

each J is independently halogen, C1-6 aliphatic, —NO 2 , —CN, N(R $ ) 2 , —OR $ , —COR $ , —CON(R $ ) 2 , —CO 2 R $ , oxo or haloC1-4 aliphatic.

11. The compound of claim 10 wherein:

M2 is —OR $ , —N(R $ ) 2 , —C(O)R $ , —C(O) 2 R R $ , —S(O)R $ , or —S(O) 2 R $ , pyridyl, pyrazinyl, pyrimidinyl, pyrrolyl, imidazolyl, pyrazolyl, furyl, tetrahydrofuryl, thienyl, tetrahydrothienyl, pyranyl, tetrahydropyranyl, isooxazolyl, piperidinyl, pyrrolidinyl, cyclopentyl, cyclohexyl, cyclopropyl, naphthyl, or phenyl, wherein M2 is optionally and independently substituted with one or more J; or M2 is absent, —N(O) 2 , or —CN; and

each J is independently halogen, C1-6 aliphatic, —NO 2 , —CN, —N(R $ ) 2 , —OR $ , oxo, or haloC1-4 aliphatic.

12. The compound of claim 1 wherein Q2 is represented by the following structural formula:

t is 0 or 1; and

q is 0 or 1.

13. The compound of claim 12 wherein the compound is represented by a structural formula selected from the group consisting of:

14. A composition comprising a compound of pharmaceutically acceptable salt thereof according to claim 1 , and a pharmaceutically acceptable carrier, adjuvant, or vehicle.